Chronic Granulomatous Disease: Lessons from a Rare Disorder

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Segal, Brahm H ^a   Veys, Paul ^b   Malech, Harry ^c   Cowan, Morton J ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic granulomatous disease; Gene therapy; Hematopoietic cell transplantation; NADPH oxidase

Indexed keywords

ALEMTUZUMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DICLOXACILLIN; FLUDARABINE; ITRACONAZOLE; LENTIVIRUS VECTOR; MELPHALAN; POSACONAZOLE; RAPAMYCIN; RECOMBINANT GAMMA INTERFERON; THYMOCYTE ANTIBODY; TREOSULFAN; VORICONAZOLE;

ARTICLE; BLOOD CULTURE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INFLAMMATION; LUNG LAVAGE; MUTAGENESIS; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OPEN LUNG BIOPSY; PATIENT CARE; REDUCED INTENSITY CONDITIONING; SPUTUM CULTURE; TRANSTHORACIC ASPIRATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X RAY ANALYSIS;

EID: 78650647287     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.09.008     Document Type: Article

References (45)

1. Winkelstein J.A., Marino M.C., Johnston R.B., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79:155-169.
2. Reeves E.P., Lu H., Jacobs H.L., et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002, 416:291-297.
3. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
4. Bianchi M., Hakkim A., Brinkmann V., et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009, 114:2619-2622.
5. Fuchs T.A., Abed U., Goosmann C., et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007, 176:231-241.
6. van den Berg J.M., van Koppen E., Ahlin A., et al. Chronic granulomatous disease: the European experience. PLoS ONE 2009, 4:e5234.
7. Marciano B.E., Rosenzweig S.D., Kleiner D.E., et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004, 114:462-468.
8. Siddiqui S., Anderson V.L., Hilligoss D.M., et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007, 45:673-681.
9. Morgenstern D.E., Gifford M.A., Li L.L., Doerschuk C.M., Dinauer M.C. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 1997, 185:207-218.
10. Romani L., Fallarino F., De Luca A., et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008, 451:211-215.
11. Segal B.H., Han W., Bushey J.J., et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS ONE 2010, 5:e9631.
12. Gallin J.I., Alling D.W., Malech H.L., et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003, 348:2416-2422.
13. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991, 324:509-516. The International Chronic Granulomatous Disease Cooperative Study Group.
14. Segal B.H., DeCarlo E.S., Kwon-Chung K.J., et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998, 77:345-354.
15. Seger R.A. Modern management of chronic granulomatous disease. Br J Haematol 2008, 140:255-266.
16. Seger R.A., Gungor T., Belohradsky B.H., et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002, 100:4344-4350.
17. Soncini E., Slatter M.A., Jones L.B., et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009, 145:73-83.
18. Güngör T., Halter J., Klink A., et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005, 79:1596-1606.
19. Güngör T., Halter J., Stussi G., Scherer F., Schanz U., Seger R. Successful busulphan-based reduced intensity conditioning in high-risk paediatric and adult chronic granulomatous disease-The Swiss experience. Bone Marrow Transplant 2009, 43(Suppl 1):S75.
20. Suzuki N., Hatakeyama N., Yamamoto M., et al. Treatment of McLeod phenotype chronic granulomatous disease with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation. Int J Hematol 2007, 85:70-72.
21. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplant in children with primary immunodeficiency using a reduced intensity conditioning regimen. Blood 2005, 105:879-885.
22. Greystoke B., Bonanomi S., Carr T.F., et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008, 142:257-262.
23. Horwitz M.E., Barrett A.J., Brown M.R., et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001, 344:881-888.
24. Duke K. Belgian loophole allows Swiss parents a " saviour" baby. Lancet 2006, 368:355-356.
25. Malech H.L., Maples P.B., Whiting-Theobald N., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997, 94:12133-12138.
26. Vowells S.J., Fleisher T.A., Sekhsaria S., Alling D.W., Maguire T.E., Malech H.L. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr 1996, 128:104-107.
27. Malech H.L. Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells 2000, 18:155-156.
28. Malech H.L., Choi U., Brenner S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn J Infect Dis 2004, 57:S27-S28.
29. Hacein-Bey-Abina S., Le Deist F., Carlier F., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185-1193.
30. Gaspar H.B., Parsley K.L., Howe S., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364:2181-2187.
31. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
32. Howe S.J., Mansour M.R., Schwarzwaelder K., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
33. Blaese R.M., Culver K.W., Miller A.D., et al. T lymphocyte-directed gene therapy for ADA-SCID initial trial results after 4 years. Science 1995, 270:475-480.
34. Bordignon C., Notarangelo L.D., Nobili N., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995, 270:470-475.
35. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
36. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360:447-458.
37. Gaspar H.B., Bjorkegren E., Parsley K., et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006, 14:505-513.
38. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401-409.
39. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
40. Kang E.M., Choi U., Theobald N., et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115:783-791.
41. Montini E., Cesana D., Schmidt M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119:964-975.
42. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
43. Moreno-Carranza B., Gentsch M., Stein S., et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009, 16:111-118.
44. Zhou S., Mody D., DeRavin S.S., et al. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 2010, 116:900-908.
45. Throm R.E., Ouma A.A., Zhou S., et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009, 113:5104-5110.